Your browser doesn't support javascript.
loading
An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
Bonnici, André; Ruiner, Carola-Ellen; St-Laurent, Lyne; Hornstein, David.
  • Bonnici A; McGill University Health Centre, Montreal, Quebec, Canada. andre.bonnici@muhc.mcgill.ca
Ann Pharmacother ; 44(9): 1504-7, 2010 Sep.
Article en En | MEDLINE | ID: mdl-20628041
ABSTRACT

OBJECTIVE:

To describe a probable interaction between enteral feeds and levodopa leading to neuroleptic malignant-like syndrome (NMLS) in a polytrauma patient with Parkinson's disease (PD). CASE

SUMMARY:

A 63-year-old morbidly obese male polytrauma patient with PD and type 2 diabetes mellitus was admitted to our intensive care unit postoperatively. Enteral feeds were administered per nasogastric tube and provided 0.88 g /kg/day of protein based on ideal body weight (IBW). His PD medications (pramipexole, entacapone, and immediate-release levodopa/carbidopa 100 mg/25 mg, 1.5 tablets 4 times daily) were administered via nasogastric tube. To achieve better glycemic control, his enteral feeds were changed to a formula that provided 1.8 g/kg/day of protein based on IBW. In the following 24 hours, the patient's mental status deteriorated and he was reintubated. He developed a high fever (40.5 degrees C), leukocytosis, elevated serum creatine kinase (CK) (480-1801 units/L), and acute renal impairment. His enteral nutrition was changed to decrease protein intake to 1.0 g/kg/day based on IBW and he was given bromocriptine 5 mg 3 times daily via nasogastric tube. Within 24 hours, the patient's mental status improved, his temperature and CK decreased, and his renal function began to improve; the values returned to baseline levels on the 18th day of admission.

DISCUSSION:

Withdrawal or dose reduction of levodopa in patients with PD has been reported to precipitate NMLS, which is potentially fatal. Because dietary protein can decrease the absorp0tion of levodopa, a potential for an interaction between levodopa and enteral feedings exists, although published reports of such an interaction are limited. In this patient, the likelihood that a drug-nutrient interaction occurred between levodopa and enteral feedings is considered to be probable based on the Naranjo probability scale and the Horn Drug Interaction Probability Scale.

CONCLUSIONS:

Health-care professionals should be aware of the interaction between levodopa and protein content of enteral nutrition to avoid the occurrence of NMLS in patients with PD.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Levodopa / Nutrición Enteral / Interacciones Alimento-Droga / Síndrome Neuroléptico Maligno / Antiparkinsonianos Límite: Humans / Male / Middle aged Idioma: En Año: 2010 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Levodopa / Nutrición Enteral / Interacciones Alimento-Droga / Síndrome Neuroléptico Maligno / Antiparkinsonianos Límite: Humans / Male / Middle aged Idioma: En Año: 2010 Tipo del documento: Article